Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583977 | 0.79 | — | — | |
| SCHEMBL1832056 | 0.79 | — | — | |
| SCHEMBL18358128 | 0.79 | — | — | |
| SCHEMBL7914616 | 0.79 | — | — | |
| SCHEMBL22630165 | 0.79 | — | — | |
| SCHEMBL19422887 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL29044201 | 0.77 | BRD4 (0.39) | BRD4BRD2KMT2ACHRM2CHRM4 | |
| SCHEMBL14275863 | 0.76 | BRD4 (0.48) | BRD4BRD2SRD5A1 | |
| SCHEMBL10491057 | 0.74 | RAB9A (0.56) | RAB9ANPC1MEN1KMT2APOLB | |
| SCHEMBL21254092 | 0.72 | BRD4 (0.45) | BRD4BRD2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3844212-B1 | EXTRUDABLE POLY(PROPYLENE) COATING COMPOSITIONS | IBM (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-115105421-A | Oral care compositions | 高露洁-棕榄公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-109982682-B | Oral care compositions | 高露洁-棕榄公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-113226280-A | Oral care compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer and methods thereof | 高露洁-棕榄公司 | 2021-08-06 | — | — | CN | disclosed |
| WO-2021038068-A1 | ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-03-04 | — | — | WO | disclosed |
| US-10745579-B2 | Extrudable poly(propylene) compositions | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20200071557-A1 | EXTRUDABLE POLY(PROPYLENE) COMPOSITIONS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-03-05 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | BRD4 1340/4885BRD2 2836/4885RAB9A 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.